TY - JOUR
T1 - Development of a multivariable normal tissue complication probability (NTCP) model for tube feeding dependence after curative radiotherapy/chemo-radiotherapy in head and neck cancer
AU - Wopken, Kim
AU - Bijl, Hendrik P.
AU - van der Schaaf, Arjen
AU - van der Laan, Hans Paul
AU - Chouvalova, Olga
AU - Steenbakkers, Roel J. H. M.
AU - Doornaert, Patricia
AU - Slotman, Ben J.
AU - Oosting, Sjoukje F.
AU - Christianen, Miranda E. M. C.
AU - van der Laan, Bernard F. A. M.
AU - Roodenburg, Jan L. N.
AU - Leemans, C. Rene
AU - Verdonck-de Leeuw, Irma M.
AU - Langendijk, Johannes A.
N1 - Copyright © 2014 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.
PY - 2014/10
Y1 - 2014/10
N2 - Background and purpose: Curative radiotherapy/chemo-radiotherapy for head and neck cancer (HNC) may result in severe acute and late side effects, including tube feeding dependence. The purpose of this prospective cohort study was to develop a multivariable normal tissue complication probability (NTCP) model for tube feeding dependence 6 months (TUBEM6) after definitive radiotherapy, radiotherapy plus cetuximab or concurrent chemoradiation based on pre-treatment and treatment characteristics.Materials and methods: The study included 355 patients with HNC. TUBEM6 was scored prospectively in a standard follow-up program. To design the prediction model, the penalized learning method LASSO was used, with TUBEM6 as the endpoint.Results: The prevalence of TUBEM6 was 10.7%. The multivariable model with the best performance consisted of the variables: advanced T-stage, moderate to severe weight loss at baseline, accelerated radiotherapy, chemoradiation, radiotherapy plus cetuximab, the mean dose to the superior and inferior pharyngeal constrictor muscle, to the contralateral parotid gland and to the cricopharyngeal muscle.Conclusions: We developed a multivariable NTCP model for TUBEM6 to identify patients at risk for tube feeding dependence. The dosimetric variables can be used to optimize radiotherapy treatment planning aiming at prevention of tube feeding dependence and to estimate the benefit of new radiation technologies. (C) 2014 The Authors. Published by Elsevier Ireland Ltd.
AB - Background and purpose: Curative radiotherapy/chemo-radiotherapy for head and neck cancer (HNC) may result in severe acute and late side effects, including tube feeding dependence. The purpose of this prospective cohort study was to develop a multivariable normal tissue complication probability (NTCP) model for tube feeding dependence 6 months (TUBEM6) after definitive radiotherapy, radiotherapy plus cetuximab or concurrent chemoradiation based on pre-treatment and treatment characteristics.Materials and methods: The study included 355 patients with HNC. TUBEM6 was scored prospectively in a standard follow-up program. To design the prediction model, the penalized learning method LASSO was used, with TUBEM6 as the endpoint.Results: The prevalence of TUBEM6 was 10.7%. The multivariable model with the best performance consisted of the variables: advanced T-stage, moderate to severe weight loss at baseline, accelerated radiotherapy, chemoradiation, radiotherapy plus cetuximab, the mean dose to the superior and inferior pharyngeal constrictor muscle, to the contralateral parotid gland and to the cricopharyngeal muscle.Conclusions: We developed a multivariable NTCP model for TUBEM6 to identify patients at risk for tube feeding dependence. The dosimetric variables can be used to optimize radiotherapy treatment planning aiming at prevention of tube feeding dependence and to estimate the benefit of new radiation technologies. (C) 2014 The Authors. Published by Elsevier Ireland Ltd.
KW - Head and neck cancer
KW - IMRT
KW - (chemo-)radiotherapy
KW - INTENSITY-MODULATED RADIOTHERAPY
KW - SQUAMOUS-CELL CARCINOMA
KW - PERCUTANEOUS ENDOSCOPIC GASTROSTOMY
KW - LOCALLY-ADVANCED HEAD
KW - SWALLOWING DYSFUNCTION
KW - RADIATION-THERAPY
KW - OROPHARYNGEAL CANCER
KW - VOLUME PARAMETERS
KW - REDUCE DYSPHAGIA
KW - STICKY SALIVA
U2 - 10.1016/j.radonc.2014.09.013
DO - 10.1016/j.radonc.2014.09.013
M3 - Article
C2 - 25443500
VL - 113
SP - 95
EP - 101
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
SN - 0167-8140
IS - 1
ER -